comparemela.com

Page 2 - Transforming Outcomes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

Faculty delve into potential challenges related to the management of patients with AL amyloidosis and cardiac involvement, discussing the associated prognostic implications.

Transforming outcomesPrecision medicineTargeted therapiesLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needsManaging al amyloidosisTreating al amyloidosis

Optimizing Treatment Management Strategies in AL Amyloidosis with CD-38-Directed mAbs

Faculty share insights into the treatment strategies using CD-38-directed monoclonal antibodies in patients with AL amyloidosis.

Transforming outcomesPrecision medicineTargeted therapiesTreatment management strategiesLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needsManaging al amyloidosis

Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

Jeffrey Zonder, MD provides an overview of treatment strategies using monoclonal antibodies for the treatment of AL amyloidosis.

Jeffrey zonderTransforming outcomesPrecision medicineTargeted therapiesStrategies using monoclonal antibodiesLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needs

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Transforming outcomesHepatocellular carcinomaExpert insightsApplying evidenceIntermediate stageSystemic therapyBclc stage bPatient selectionLiver functionTumor boardPhase iii studiesPhase 3 studiesLiver directed therapyOpen label phase iiHigh afp

Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Transforming outcomesHepatocellular carcinomaExpert insightsApplying evidenceAngiogenic systemic therapiesSecond lineIntermediate stageSystemic therapyBclc stage bPatient selectionLiver functionTumor boardPhase iii studiesPhase 3 studiesLiver directed therapyOpen label phase ii

vimarsana © 2020. All Rights Reserved.